Yuankang Pharmaceutical (688658.SH): Clinical trial approval for the new indication of YKYY017 aerosol inhalation agent granted by the National Medical Products Administration.

According to the Zhitong Finance APP, Yuyuan Pharmaceutical (688658.SH) recently announced that the company has received the "Approval Notice for Clinical Trials of Drugs" from the National Medical Products Administration (referred to as "NMPA"), which authorizes the use of the YKYY017 aerosol inhalation agent for the treatment and prevention of respiratory infections related to human coronavirus OC43 (HCoV-OC43).